These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 9815793

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
    Haas C, Strauss G, Moldenhauer G, Iorio RM, Schirrmacher V.
    Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
    [Abstract] [Full Text] [Related]

  • 4. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.
    Ertel C, Millar NS, Emmerson PT, Schirrmacher V, von Hoegen P.
    Eur J Immunol; 1993 Oct; 23(10):2592-6. PubMed ID: 8405059
    [Abstract] [Full Text] [Related]

  • 5. Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus.
    Fournier P, Zeng J, Von Der Lieth CW, Washburn B, Ahlert T, Schirrmacher V.
    Int J Oncol; 2004 Mar; 24(3):623-34. PubMed ID: 14767547
    [Abstract] [Full Text] [Related]

  • 6. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C, Lulei M, Fournier P, Arnold A, Schirrmacher V.
    Vaccine; 2005 Mar 31; 23(19):2439-53. PubMed ID: 15752830
    [Abstract] [Full Text] [Related]

  • 7. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
    Aigner M, Janke M, Lulei M, Beckhove P, Fournier P, Schirrmacher V.
    Int J Oncol; 2008 Apr 31; 32(4):777-89. PubMed ID: 18360705
    [Abstract] [Full Text] [Related]

  • 8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 31; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

  • 9. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E, Carreño LJ, González PA, Kalergis AM.
    Eur J Immunol; 2009 Aug 31; 39(8):2259-69. PubMed ID: 19637198
    [Abstract] [Full Text] [Related]

  • 10. Melanoma vaccine based on the vector of membrane fusogenic liposomes.
    Qiang L, Yi J, Fu-De C.
    Pharmazie; 2004 Apr 31; 59(4):263-7. PubMed ID: 15125569
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
    Haas C, Herold-Mende C, Gerhards R, Schirrmacher V.
    Cancer Gene Ther; 1999 Apr 31; 6(3):254-62. PubMed ID: 10359211
    [Abstract] [Full Text] [Related]

  • 14. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F, Mao YQ, Kan B, He QM, Jiang Y, Peng F, Yang L, Tian L.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov 31; 35(6):757-60. PubMed ID: 15573746
    [Abstract] [Full Text] [Related]

  • 15. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J, Souberbielle BE, Sheikh N, Morrow WJ, Scott-Taylor T, Vile R, Chong H, Dalgleish AG.
    Gene Ther; 1999 Aug 31; 6(8):1475-81. PubMed ID: 10467372
    [Abstract] [Full Text] [Related]

  • 16. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.
    Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G.
    J Immunol; 1995 Apr 01; 154(7):3406-19. PubMed ID: 7897222
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV).
    Plaksin D, Porgador A, Vadai E, Feldman M, Schirrmacher V, Eisenbach L.
    Int J Cancer; 1994 Dec 15; 59(6):796-801. PubMed ID: 7989121
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.